clinical trial · NCT06036121
A Study of ADRX-0706 in Select Advanced Solid Tumors
Solid TumorsTriple Negative Breast Cancer (TNBC)Urothelial CancerCervical CancerADRX-0706
brief summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
started
Sep 26, 2023
primary completion
Sep 1, 2025
completion
Dec 1, 2026
last updated
Aug 17, 2025
detailed description
This is a 2 part study. The Phase 1a will consist of a dose escalation of ADRX-0706 to evaluate initial safety and tolerability in patients with select advanced solid tumors, and to identify the recommended dose to be used in the Phase 1b. The Phase 1b will further evaluate the safety and tolerability, as well as preliminary efficacy, and identify the optimal dose of ADRX-0706 in patients with urothelial cancer, triple negative breast cancer, and cervical cancer.
official title
A Phase 1a/b Study of ADRX-0706 in Subjects With Select Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol